文献速递认知障碍与痴呆

MAPT突变携带者额叶1H磁共振波谱研究

Frontal lobe 1H MR spectroscopy in asymptomatic and symptomatic MAPT mutation carriers.
PubMed 文献 · Neurology · 2019-07-17

该研究纳入5个家系的MAPT突变携带者(无症状9例、有症状10例)及健康非携带者对照25例,采用3T单 voxel 1H MRS测量额叶内侧代谢物比值。结果显示无症状携带者NAA/Cr和NAA/mI已降低,有症状携带者NAA/Cr、NAA/mI降低且mI/Cr升高,提示额叶神经化学改变早于症状出现。

要点

  • 无症状MAPT突变携带者额叶NAA/Cr和NAA/mI已较非携带者降低。
  • 有症状携带者NAA/Cr、NAA/mI降低且mI/Cr升高更显著。
  • 额叶1H MRS可能作为MAPT突变携带者早期神经退行性变的生物标志物。

核心结论

  • 额叶1H MRS测得的神经化学改变在MAPT突变携带者症状出现前即已存在。
  • 额叶1H MRS是MAPT突变携带者早期神经退行性过程的潜在生物标志物。

研究设计与样本

  • 研究纳入来自5个家系的MAPT突变携带者,在Mayo Clinic site的LEFFTDS研究中于3T行额叶内侧单 voxel 1H MRS(n=19)。
  • 无症状携带者9例(FTLD-CDR SOB评分为0),有症状携带者10例(FTLD-CDR SOB中位评分5)。
  • 健康一级亲属中的非携带者作为对照(n=25)。
  • 人口学特征和1H MRS代谢物比值比较采用Fisher精确检验(性别)和线性混合模型(校正家系内相关性),两两比较用Tukey对比。

主要发现

  • 校正年龄后,无症状MAPT突变携带者较非携带者NAA/Cr降低(p=0.001)、NAA/mI降低(p=0.026)。
  • 校正年龄后,有症状MAPT突变携带者较非携带者NAA/Cr降低(p=0.01)、NAA/mI降低(p=0.01)、mI/Cr升高(p=0.02)。
  • 随着携带者年龄接近和超过症状出现年龄,NAA/Cr(p=0.006)和NAA/mI(p<0.001)比值下降,伴mI/Cr比值升高(p=0.001)。

临床怎么用

  • 对于MAPT突变携带者,额叶1H MRS代谢物比值(NAA/Cr、NAA/mI、mI/Cr)可作为早期神经退行性变的监测指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the frontal lobe proton magnetic resonance spectroscopy (1H MRS) abnormalities in asymptomatic and symptomatic carriers of microtubule-associated protein tau (MAPT) mutations. METHODS: We recruited patients with MAPT mutations from 5 individual families, who underwent single voxel 1H MRS from the medial frontal lobe at 3T (n = 19) from the Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS) Study at the Mayo Clinic site. Asymptomatic MAPT mutation carriers (n = 9) had Frontotemporal Lobar Degeneration Clinical Dementia Rating Sum of Boxes (FTLD-CDR SOB) score of zero, and symptomatic MAPT mutation carriers (n = 10) had a median FTLD-CDR SOB score of 5. Noncarriers from healthy first-degree relatives of the patients were recruited as controls (n = 25). The demographic aspects and 1H MRS metabolite ratios were compared by use of the Fisher exact test for sex and linear mixed models to account for within-family correlations. We used Tukey contrasts for pair-wise comparisons. RESULTS: Asymptomatic MAPT mutation carriers had lower neuronal marker N-acetylaspartate (NAA)/creatine (Cr) (p = 0.001) and lower NAA/myo-inositol (mI) (p = 0.026) than noncarriers after adjustment for age. Symptomatic MAPT mutation carriers had lower NAA/Cr (p = 0.01) and NAA/mI (p = 0.01) and higher mI/Cr (p = 0.02) compared to noncarriers after adjustment for age. Furthermore, NAA/Cr (p = 0.006) and NAA/mI (p < 0.001) ratios decreased, accompanied by an increase in mI/Cr ratio (p = 0.001), as the ages of carriers approached and passed the age at symptom onset. CONCLUSION: Frontal lobe neurochemical alterations measured with 1H MRS precede the symptom onset in MAPT mutation carriers. Frontal lobe 1H MRS is a potential biomarker for early neurodegenerative processes in MAPT mutation carriers.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Chen Q, Boeve BF, Tosakulwong N, et al. Frontal lobe 1H MR spectroscopy in asymptomatic and symptomatic MAPT mutation carriers. Neurology. 2019. PMID: 31315971. doi:10.1212/WNL.0000000000007961

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。